Clinical trial Recruiting at 1 site Observational Ages 18 and up

Understanding hemorrhage subtypes in perimesencephalic SAH and basilar artery perforator aneurysms

Official title: Determining the Clinical Impact and Prevalence of Hemorrhagic Subtypes in Perimesencephalic Subarachnoid Hemorrhage - A Prospective Observational Study

Run by Insel Gruppe AG, University Hospital Bern · NCT07923084 · Data updated 2026-11-12

This study tests whether different bleeding patterns in pmSAH, including potential basilar artery perforator aneurysms, relate to patient outcomes using a patient-reported EQ-5D measure.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment264 (estimated)
SponsorInsel Gruppe AG, University Hospital Bern
Academic / other
Locations1 site (Bern)
StatusRecruiting
StartedJanuary 1, 2026
Main results expectedMarch 31, 2029
Study endsMarch 31, 2029
Registry record updatedNovember 6, 2026
Trial IDNCT07923084 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 or older with non-traumatic pmSAH (or pmSAH with minimal additional blood) who have baseline CT or MRI imaging and can consent.

Probably not a fit

Patients with traumatic SAH, alternative aneurysm sources in the posterior circulation, or severe renal impairment may not derive direct benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects baseline imaging and patient-reported outcomes to describe the prevalence and clinical impact of hemorrhagic subtypes in perimesencephalic subarachnoid hemorrhage. Participants are adults with non-traumatic pmSAH (or pmSAH with limited adjacent blood) who provide informed consent and complete the EQ-5D questionnaire. The study analyzes PROM data alongside imaging findings to explore links between vascular lesions such as basilar artery perforator aneurysms and functional outcomes. No interventional treatment is performed; the focus is on characterization and correlation of imaging features with patient-reported quality of life. Results may improve understanding of pmSAH prognosis and guide future research on targeted management.

Why it matters

Potential benefit: If successful, findings could improve risk stratification and inform prognosis for patients with pmSAH and related lesions.

How similar studies have gone: Previous multicenter data suggest vascular lesions like BAPAs can be associated with worse outcomes, but prospective PROM-based characterization in pmSAH is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients aged ≥18 years with a non-traumatic pmSAH or limited additional blood in adjacent cisterns (pmSAH "plus")
* Cross-sectional imaging at baseline (CT or MRI)
* Written informed consent for study participation was obtained.

Exclusion Criteria:

* Presence of documented written or verbal refusal
* pmSAH patients with a presumed traumatic source
* Saccular/fusiform aneurysm of the main arteries of the posterior circulation (e.g. V4, AICA, PICA, basilar trunk, basilar tip)
* pmSAH patients with a shunting lesion in the vertebrobasilar territory (i.e. brain AVM, brain/spine AVF)
* pmSAH patients with a cavernous malformation in the posterior fossa
* Basilar artery perforator aneurysm group (BAPA group):
* Aneurysm arising from the basilar artery trunk adjacent to a perforating branch but not involving a perforating artery (Satti Type 1)
* Flow-related BAPA (i.e. AVM, AVF)
* Severely impaired renal function defined as KDIGO grade 4 (GFR \<30 mL/min/1.73 m2)
* Pregnancy or suspected pregnancy
* Known adverse events to iodinated contrast media

Where it's running

  • Inselspital, University Hospital Bern
    Bern, Switzerland
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.